Modulators of hedgehog signaling pathways, compositions and uses related thereto
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. Such methods and reagents may also inhibit the hedgehog pathway in normal cells, e.g., where normal levels of hedgehog signalling are unwanted.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having a structure of Formula VI:
wherein, as valence and stability permit,
each Ar is independently selected from the group consisting of a substituted phenyl and unsubstituted phenyl;
W is selected from the group consisting of C═O, C═S, and SO 2 ;
each of X and X 1 is independently selected from the group consisting of N and CR′;
R′ is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, aryl, hydroxyl, alkoxyl, silyloxy, amino, alkylamino, nitro, cyano, thiol, amino, imino, amido, phosphoryl, phosphonate, carboxyl, carboxamide, anhydride, silyl, thioether, alkylsulfonyl, arylsulfonyl, selenoether, acyl, aldehyde, ester, carbamate, and carbonate; and
R 9 represents 0 to 4 substituents on the ring to which it is attached, the substituents being independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, aryl, alkoxyl, silyloxy, amino, nitro, cyano, thiol, amino, alkylamino, imino, amido, phosphoryl, phosphonate, carboxyl, carboxamide, anhydride, silyl, thioether, alkylsulfonyl, arylsulfonyl, selenoether, acyl, aldehyde, ester, carbamate, and carbonate,
or a pharmaceutically acceptable salt thereof.
2. A composition of claim 1 , wherein X is N, X 1 is CR′, and each R 9 is selected from the group consisting of halogen, alkyl, cyano, nitro and R 9 is absent.
3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having a structure:
wherein, as valence and stability permit,
each of Ar and Ar 1 , is independently selected from the group consisting of a substituted aryl, an unsubstituted aryl and a heteroaryl, with the further proviso that Ar is a single-ring moiety;
W is selected from the group consisting of C═O, C═S, and SO 2 ;
each of X and X 1 is independently selected from the group consisting of N and CR′;
R′ is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, aryl, hydroxyl, alkoxyl, silyloxy, amino, alkylamino, nitro, cyano, thiol, amino, imino, amido, phosphoryl, phosphonate, carboxyl, carboxamide, anhydride, silyl, thioether, alkylsulfonyl, arylsulfonyl, selenoether, acyl, aldehyde, ester, carbamate, and carbonate; and
R 9 is absent;
or a pharmaceutically acceptable salt thereof.
4. The composition of claim 3 , wherein each of Ar and Ar 1 is selected from the group consisting of a substituted phenyl, and unsubstituted phenyl, X is N, and X 1 is CR′.
5. A pharmaceutical composition, comprising a pharmaceutically acceptable excipient and a compound having the formula:
6. The composition of claim 1 , wherein W is C═O and R 9 is absent.
7. The composition of claim 2 , wherein W is C═O and R 9 is absent.